Literature DB >> 11742917

Pulmonary infectious mortality among patients with end-stage renal disease.

M J Sarnak1, B L Jaber.   

Abstract

BACKGROUND: Infection is the second-leading cause of death among patients with end-stage renal disease (ESRD). This is due in part to advanced age, comorbid conditions, and immune dysfunction observed in uremic states. Although one may hypothesize that pulmonary infectious mortality is higher among patients with ESRD compared with the general population (GP), no such data are currently available.
METHODS: We compared annual pulmonary infectious mortality rates among patients with ESRD to those in the GP. The data were abstracted from the United States Renal Data System and the National Center for Health Statistics, respectively, and were stratified by age, gender, race, and presence or absence of diabetes mellitus (DM). In the GP, primary and multiple cause-of-death analyses were performed to account for potential limitations of the data sources.
RESULTS: Overall, pulmonary infectious mortality rate was 14-fold to 16-fold higher in dialysis patients and approximately twofold higher in renal transplant recipients compared with the GP. After stratification for age, differences between groups decreased but retained their magnitude.
CONCLUSION: Patients with ESRD treated with dialysis have higher pulmonary infectious mortality rates compared with the GP, even after stratification for age, race, and DM. Consequently, this patient population must be considered at high risk for the development of lethal pulmonary infections.

Entities:  

Mesh:

Year:  2001        PMID: 11742917     DOI: 10.1378/chest.120.6.1883

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  60 in total

1.  Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients.

Authors:  Nicolas Simon; Bertrand Dussol; Emmanuelle Sampol; Raj Purgus; Philippe Brunet; Bruno Lacarelle; Yvon Berland; Bernard Bruguerolle; Saïk Urien
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Secular Trends in Infection-Related Mortality after Kidney Transplantation.

Authors:  Susanna Kinnunen; Pauli Karhapää; Auni Juutilainen; Patrik Finne; Ilkka Helanterä
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-05       Impact factor: 8.237

Review 3.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

4.  Efficacy of a liver resection for hepatocellular carcinoma in patients with chronic renal failure.

Authors:  Takashi Orii; Tetsuro Takayama; Izumi Haga; Tatsuya Fukumori; Noritoshi Amada
Journal:  Surg Today       Date:  2008-03-27       Impact factor: 2.549

5.  Active vitamin D and acute respiratory infections in dialysis patients.

Authors:  Yoshihiro Tsujimoto; Hideki Tahara; Tetsuo Shoji; Masanori Emoto; Hidenori Koyama; Eiji Ishimura; Tsutomu Tabata; Yoshiki Nishizawa; Masaaki Inaba
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

6.  Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients 50 Years and Older with End-Stage Renal Disease and on Dialysis.

Authors:  Subhashis Mitra; Gary E Stein; Shyam Bhupalam; Daniel H Havlichek
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

Review 7.  Infectious complications in dialysis--epidemiology and outcomes.

Authors:  Philip Kam-Tao Li; Kai Ming Chow
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

8.  Infections in hemodialysis: a concise review - Part 1: bacteremia and respiratory infections.

Authors:  T Eleftheriadis; V Liakopoulos; K Leivaditis; G Antoniadi; I Stefanidis
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

9.  IκB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD.

Authors:  Jianmin Chen; Julius E Kieswich; Fausto Chiazza; Amie J Moyes; Thomas Gobbetti; Gareth S D Purvis; Daniela C F Salvatori; Nimesh S A Patel; Mauro Perretti; Adrian J Hobbs; Massimo Collino; Muhammad M Yaqoob; Christoph Thiemermann
Journal:  J Am Soc Nephrol       Date:  2016-05-06       Impact factor: 10.121

10.  Hyperleptinemia is associated with impaired pulmonary host defense.

Authors:  Niki D J Ubags; Renee D Stapleton; Juanita H J Vernooy; Elianne Burg; Jenna Bement; Catherine M Hayes; Sebastian Ventrone; Lennart Zabeau; Jan Tavernier; Matthew E Poynter; Polly E Parsons; Anne E Dixon; Matthew J Wargo; Benjamin Littenberg; Emiel F M Wouters; Benjamin T Suratt
Journal:  JCI Insight       Date:  2016-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.